Advertisement

Ola Landgren, MD, PhD, Joins Sylvester Comprehensive Cancer Center at University of Miami


Advertisement
Get Permission

Ola Landgren, MD, PhD

Ola Landgren, MD, PhD

Hematologic oncologist Ola Landgren, MD, PhD, was recently appointed the inaugural leader of a new research program, Experimental Therapeutics, at Sylvester Comprehensive Cancer Center at the University of Miami Health System and the Miller School of Medicine. Dr. Landgren, who was Chief of Myeloma Service for the past 6 years at Memorial Sloan Kettering Cancer Center, will also serve as Chief of the Myeloma Program at Sylvester.

“We are delighted to have Dr. Landgren as a colleague. He is a world leader with great vision and expertise,” said Stephen D. Nimer, MD, Director at Sylvester. “He will help us develop effective new treatments and new lines of research.”

Seeking Advancements in Research and Treatment

“I am thrilled to join Sylvester Comprehensive Cancer Center, South Florida’s only NCI [National Cancer Institute]-designated cancer center. It is a vibrant institution with outstanding people, access to all the leading technologies, and lots of positive energy,” said Dr. Landgren. “For me, it is a unique opportunity to both deepen and broaden the type of work I have done for many years. Our ongoing work focusing on genomic characterization of tumor cells and cells in the tumor microenvironment is already at the forefront, and we will keep on pushing the envelope.”

Stephen D. Nimer, MD

Stephen D. Nimer, MD

The Experimental Therapeutics Program will bring together multidisciplinary teams of clinicians and scientists throughout Sylvester. The teams will work together to advance research into novel therapies and to accelerate discoveries from the laboratory to the bedside. In addition to supporting early laboratory discoveries, they will focus on the refinement of preclinical models as well as early-stage and first-in-human clinical trials—all with the overall goal of moving therapeutic advances forward and facilitating U.S. Food and Drug Administration approvals so that patients will have access to newer and better therapies. 


Advertisement

Advertisement



Advertisement